Plummer-Vinson syndrome secondary prevention: Difference between revisions
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
Line 2: | Line 2: | ||
{{Plummer-Vinson syndrome}} | {{Plummer-Vinson syndrome}} | ||
{{CMG}}; {{AE}}{{Akshun}} | {{CMG}}; {{AE}}{{Akshun}} | ||
==Overview== | ==Overview== |
Revision as of 18:16, 1 November 2017
Plummer-Vinson syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Plummer-Vinson syndrome secondary prevention On the Web |
American Roentgen Ray Society Images of Plummer-Vinson syndrome secondary prevention |
Risk calculators and risk factors for Plummer-Vinson syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]
Overview
Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing malignant lesions (squamous cell carcinoma) of the oral mucosa, hypopharynx and esophagus. Effective measures for the secondary prevention of Plummer-Vinson syndrome include an upper gastrointestinal endoscopy every year to rule out malignant changes.
Secondary Prevention
Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing malignant lesions (squamous cell carcinoma) of the oral mucosa, hypopharynx and esophagus. Effective measures for the secondary prevention of Plummer-Vinson syndrome include:
- Upper gastrointestinal endoscopy every year